Bexarotene pointless against tumor stage mycosis fungoides
According to results from a long-term, single-center study presented at the annual meeting of the American Academy of Dermatology, oral bexarotene therapy offers absolutely nothing to patients diagnosed with tumor stage mycosis fungoides, a rather common subtype of cutaneous T-cell lymphoma.
Patients given oral bexarotene therapy experienced a median survival time of 3.3 years, compared with a median of 7.7 years survival time for patients who did not receive the drug.
Despite the frequency of the diagnosis of mycosis fungoides, no randomized controlled trials exist to compare existing therapies head to head to determine which confers the greatest benefit on the most number of patients.
Source: Family Practice News
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
